Literature DB >> 10780580

pH, healing rate, and symptom relief in patients with GERD.

J Q Huang1, R H Hunt.   

Abstract

Gastroesophageal reflux symptoms are common and occur in all of us from time to time. In others, reflux may be associated with ulcerative esophagitis. The symptoms may be aggravated by large meals, coffee, smoking and position. Physiological and pathological reflux can be separated by the frequency and duration of the exposure of the lower esophagus to acid. Pathological reflux results in symptoms and also esophagitis and ulceration in some patients. Although gastroesophageal reflux disease (GERD) is considered to result from a disorder of motility in the esophagus, gastric acid and peptic activity are deemed pivotal to the initiation and continuation of the esophageal damage and the development of symptoms. Acid exposure in the esophagus is normally less than 4 percent of the 24 hours with a pH below 4. An increase over 4 percent of the time with a pH less than 4 is considered pathological. Hence, antisecretory drugs have become the principle approach to the treatment of reflux symptoms and esophagitis since they reduce the acidity, of gastric juice and the activity of pepsin. Importantly, they also reduce the volume of gastric juice available for reflux into the esophagus. There is a clear relationship between the degree and duration of acid suppression and the relief of heartburn and healing of esophagitis. Pharmacodynamic studies with different dose regimens of the H2-receptor antagonists and the proton pump inhibitors show a difference in the degree and duration of the antisecretory effect, and this correlates closely with the results of clinical trials with respect to the healing of esophagitis and the relief of symptoms. Proton pump inhibitors achieve healing rates by week four, which are not achieved by H2-receptor antagonists even after 12 weeks of treatment. The advantage of proton pump inhibitors over H2-receptor antagonists is due to the greater degree, longer duration of effect and more complete inhibition of acid secretion that maintains intragastric pH above 4 for a maximal duration. Although there is no significant difference between proton pump inhibitors with respect to healing of esophagitis, symptom relief occurs earlier with lansoprazole than omeprazole, and this is probably due to the greater oral bioavailability and faster onset of action of lansoprazole when compared to omeprazole.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10780580      PMCID: PMC2579003     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  87 in total

Review 1.  Comparative role of omeprazole in the treatment of gastroesophageal reflux disease.

Authors:  V A Skoutakis; R H Joe; D S Hara
Journal:  Ann Pharmacother       Date:  1995-12       Impact factor: 3.154

2.  Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.

Authors:  M Sakaguchi; K Ashida; E Umegaki; H Miyoshi; K Katsu
Journal:  J Clin Gastroenterol       Date:  1995       Impact factor: 3.062

3.  A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.

Authors:  M Robinson; B Sahba; D Avner; N Jhala; P A Greski-Rose; D E Jennings
Journal:  Aliment Pharmacol Ther       Date:  1995-02       Impact factor: 8.171

4.  Combination of ranitidine and cisapride in the treatment of reflux oesophagitis.

Authors:  C J McKenna; J G Mills; C Goodwin; J R Wood
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-09       Impact factor: 2.566

5.  Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.

Authors:  K D Bardhan; C J Hawkey; R G Long; A G Morgan; K G Wormsley; I K Moules; D Brocklebank
Journal:  Aliment Pharmacol Ther       Date:  1995-04       Impact factor: 8.171

6.  Marked rebound acid hypersecretion after treatment with ranitidine.

Authors:  E el-Omar; S Banerjee; A Wirz; I Penman; J E Ardill; K E McColl
Journal:  Am J Gastroenterol       Date:  1996-02       Impact factor: 10.864

7.  Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study.

Authors:  H Koop; W Schepp; H G Dammann; A Schneider; R Lühmann; M Classen
Journal:  J Clin Gastroenterol       Date:  1995-04       Impact factor: 3.062

Review 8.  The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease.

Authors:  R H Hunt
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

Review 9.  The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease.

Authors:  D G Colin-Jones
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

Review 10.  The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease.

Authors:  K D Bardhan
Journal:  Aliment Pharmacol Ther       Date:  1995       Impact factor: 8.171

View more
  11 in total

Review 1.  Outcomes of fundoplication: causes for concern, newer options.

Authors:  E Hassall
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

2.  Gastroesophageal reflux disease: clinical features.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

3.  Assessment of In Vivo Clinical Product Performance of a Weak Basic Drug by Integration of In Vitro Dissolution Tests and Physiologically Based Absorption Modeling.

Authors:  Xuan Ding; Ivelina Gueorguieva; James A Wesley; Lee J Burns; Carrie A Coutant
Journal:  AAPS J       Date:  2015-07-01       Impact factor: 4.009

4.  Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease.

Authors:  Shih-Chi Ho; Chi-Sen Chang; Chun-Ying Wu; Gran-Hum Chen
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

5.  Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.

Authors:  Theo Scholten; Iris Teutsch; Martina Bohuschke; Gudrun Gatz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Streamlining 24-hour pH study for GERD: Use of a 3-hour postprandial test.

Authors:  Amindra S Arora; Joseph A Murray
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

7.  Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.

Authors:  Clive Wilder-Smith; Anna Backlund; Göran Eckerwall; Tore Lind; Mia Fjellman; Kerstin Röhss
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 8.  Potent Acid Suppression with PPIs and P-CABs: What's New?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

9.  A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers.

Authors:  Vijayalakshmi S Pratha; Thomas McGraw; William Tobin
Journal:  Pharmacol Res Perspect       Date:  2016-05-19

10.  The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.

Authors:  Dasohm Kim; Min Soo Park; Byung Won Yoo; Taegon Hong; Shin Jung Park; Choon Ok Kim
Journal:  Drug Des Devel Ther       Date:  2019-09-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.